US approval gives Pfizer the first and second-line settings.

But, like Merck two weeks ago, GSK has failed to hit overall survival.

Two Kelun ADCs and two actinium-based radioconjugates start phase 1.

Data deteriorate, leaving cash-strapped Affimed relying on a post-hoc analysis and higher dosing.

Merck ditches vibostolimab and favezelimab following huge pivotal programmes.

Zelenectide looks uncompetitive versus Padcev in bladder cancer, while elsewhere a biomarker strategy beckons.